SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 51.59-1.1%Dec 2 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (354)8/16/1999 3:26:00 PM
From: dalroi  Read Replies (1) of 52153
 
Mike
Just got this from IR NBIX
Neurocrine Biosciences has not halted the Phase II trial for IL-4 Fusion
Toxin (NBI-3001). We are encouraged by the preliminary safety and efficacy
results from this study that were presented in May 1999 in a publication at
The 50th Annual Meeting of the German Society of Neurosurgery in Munich.
Patient MRI scans demonstrated dramatic changes suggestive of tumor necrosis
(cell death) in major portions of the malignant brain tumors. In addition
results presented showed that there were no dose limiting toxicities
identified in this study.

The Phase II trial is continuing in the U.S. and Germany. The protocols for
the U.S. and Germany sites are different. In Germany the study is
investigating both maximum tolerated dose and maximum tolerated volume. In
the U.S. the study is investigating maximum tolerated dose and evaluating
certain efficacy measures at that dose. Enrollment in the U.S. study is
currently paused to allow the investigators and Neurocrine to evaluate the
data and determine whether maximum tolerated dose has been achieved.
Patients are currently being enrolled at the German sites pursuant to the
German protocol. In addition, Neurocrine has applied with the FDA for fast
track status for approval of NBI-3001.

Like i promised
Dalroi aka stefaan bafort (first name is stefaan)
at time i signed up with si i didnt new difference between first and last name :-(
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News